Literature DB >> 33222322

Analysis of mutational signatures with yet another package for signature analysis.

Daniel Hübschmann1,2,3,4, Lea Jopp-Saile1,2,5, Carolin Andresen2,5, Stephen Krämer5, Zuguang Gu1,6, Christoph E Heilig3,7, Simon Kreutzfeldt3,7, Veronica Teleanu3,7, Stefan Fröhling3,7, Roland Eils8,9, Matthias Schlesner5,10.   

Abstract

Different mutational processes leave characteristic patterns of somatic mutations in the genome that can be identified as mutational signatures. Determining the contributions of mutational signatures to cancer genomes allows not only to reconstruct the etiology of somatic mutations, but can also be used for improved tumor classification and support therapeutic decisions. We here present the R package yet another package for signature analysis (YAPSA) to deconvolute the contributions of mutational signatures to tumor genomes. YAPSA provides in-built collections from the COSMIC and PCAWG SNV signature sets as well as the PCAWG Indel signatures and employs signature-specific cutoffs to increase sensitivity and specificity. Furthermore, YAPSA allows to determine 95% confidence intervals for signature exposures, to perform constrained stratified signature analyses to obtain enrichment and depletion patterns of the identified signatures and, when applied to whole exome sequencing data, to correct for the triplet content of individual target capture kits. With this functionality, YAPSA has proved to be a valuable tool for analysis of mutational signatures in molecular tumor boards in a precision oncology context. YAPSA is available at R/Bioconductor (http://bioconductor.org/packages/3.12/bioc/html/YAPSA.html).
© 2020 The Authors. Genes, Chromosomes & Cancer published by Wiley Periodicals LLC.

Entities:  

Keywords:  BRCAness; YAPSA; biomarker; cancer genomics; mutational signatures; precision oncology

Mesh:

Year:  2020        PMID: 33222322     DOI: 10.1002/gcc.22918

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data.

Authors:  Xuwen Wang; Ying Xu; Yinbin Zhang; Shenjie Wang; Xuanping Zhang; Xin Yi; Shuqun Zhang; Jiayin Wang
Journal:  Front Genet       Date:  2022-09-28       Impact factor: 4.772

2.  The genomic and transcriptional landscape of primary central nervous system lymphoma.

Authors:  Josefine Radke; Naveed Ishaque; Randi Koll; Zuguang Gu; Elisa Schumann; Lina Sieverling; Sebastian Uhrig; Daniel Hübschmann; Umut H Toprak; Cristina López; Xavier Pastor Hostench; Simone Borgoni; Dilafruz Juraeva; Fabienne Pritsch; Nagarajan Paramasivam; Gnana Prakash Balasubramanian; Matthias Schlesner; Shashwat Sahay; Marc Weniger; Debora Pehl; Helena Radbruch; Anja Osterloh; Agnieszka Korfel; Martin Misch; Julia Onken; Katharina Faust; Peter Vajkoczy; Dag Moskopp; Yawen Wang; Andreas Jödicke; Lorenz Trümper; Ioannis Anagnostopoulos; Dido Lenze; Ralf Küppers; Michael Hummel; Clemens A Schmitt; Otmar D Wiestler; Stephan Wolf; Andreas Unterberg; Roland Eils; Christel Herold-Mende; Benedikt Brors; Reiner Siebert; Stefan Wiemann; Frank L Heppner
Journal:  Nat Commun       Date:  2022-05-10       Impact factor: 17.694

3.  Longitudinal genomic alternations and clonal dynamics analysis of primary malignant melanoma of the esophagus.

Authors:  Jingjing Li; Wenyan Guan; Wei Ren; Ziyao Liu; Hongyan Wu; Yiqiang Chen; Siyuan Liu; Xiangming Quan; Zuoquan Yang; Chong Jiang; Jian He; Xiao Xiao; Qing Ye
Journal:  Neoplasia       Date:  2022-06-01       Impact factor: 6.218

4.  Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma.

Authors:  Jenette Creaney; Ann-Marie Patch; Venkateswar Addala; Bruce W Robinson; Nicola Waddell; Sophie A Sneddon; Katia Nones; Ian M Dick; Y C Gary Lee; Felicity Newell; Ebony J Rouse; Marjan M Naeini; Olga Kondrashova; Vanessa Lakis; Apostolos Nakas; David Waller; Annabel Sharkey; Pamela Mukhopadhyay; Stephen H Kazakoff; Lambros T Koufariotis; Aimee L Davidson; Priya Ramarao-Milne; Oliver Holmes; Qinying Xu; Conrad Leonard; Scott Wood; Sean M Grimmond; Raphael Bueno; Dean A Fennell; John V Pearson
Journal:  Genome Med       Date:  2022-05-30       Impact factor: 15.266

5.  Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.

Authors:  Niklas Gebauer; Axel Künstner; Julius Ketzer; Hanno M Witte; Tobias Rausch; Vladimir Benes; Jürgen Zimmermann; Judith Gebauer; Hartmut Merz; Veronica Bernard; Lana Harder; Katharina Ratjen; Stefan Gesk; Wolfgang Peter; Yannik Busch; Peter Trojok; Nikolas von Bubnoff; Harald Biersack; Hauke Busch; Alfred C Feller
Journal:  Blood Cancer J       Date:  2021-05-26       Impact factor: 11.037

6.  The genomic landscape of pediatric renal cell carcinomas.

Authors:  Pengbo Beck; Barbara Selle; Lukas Madenach; David T W Jones; Christian Vokuhl; Apurva Gopisetty; Arash Nabbi; Ines B Brecht; Martin Ebinger; Jenny Wegert; Norbert Graf; Manfred Gessler; Stefan M Pfister; Natalie Jäger
Journal:  iScience       Date:  2022-03-26

7.  Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis.

Authors:  Rouven Hoefflin; Adriana Lazarou; Maria Elena Hess; Meike Reiser; Julius Wehrle; Patrick Metzger; Anna Verena Frey; Heiko Becker; Konrad Aumann; Kai Berner; Martin Boeker; Nico Buettner; Christine Dierks; Jesus Duque-Afonso; Michel Eisenblaetter; Thalia Erbes; Ralph Fritsch; Isabell Xiang Ge; Anna-Lena Geißler; Markus Grabbert; Steffen Heeg; Dieter Henrik Heiland; Simone Hettmer; Gian Kayser; Alexander Keller; Anita Kleiber; Alexandra Kutilina; Leman Mehmed; Frank Meiss; Philipp Poxleitner; Justyna Rawluk; Juri Ruf; Henning Schäfer; Florian Scherer; Khalid Shoumariyeh; Andreas Tzschach; Christoph Peters; Tilman Brummer; Martin Werner; Justus Duyster; Silke Lassmann; Cornelius Miething; Melanie Boerries; Anna L Illert; Nikolas von Bubnoff
Journal:  Cancers (Basel)       Date:  2021-03-08       Impact factor: 6.639

8.  Comparison of somatic mutation landscapes in Chinese versus European breast cancer patients.

Authors:  Bin Zhu; Lijin Joo; Tongwu Zhang; Hela Koka; DongHyuk Lee; Jianxin Shi; Priscilla Lee; Difei Wang; Feng Wang; Wing-Cheong Chan; Sze Hong Law; Yee-Kei Tsoi; Gary M Tse; Shui Wun Lai; Cherry Wu; Shuyuan Yang; Emily Ying Yang Chan; Samuel Yeung Shan Wong; Mingyi Wang; Lei Song; Kristine Jones; Bin Zhu; Amy Hutchinson; Belynda Hicks; Ludmila Prokunina-Olsson; Montserrat Garcia-Closas; Stephen Chanock; Lap Ah Tse; Xiaohong R Yang
Journal:  HGG Adv       Date:  2021-12-03

9.  A mixture model for signature discovery from sparse mutation data.

Authors:  Itay Sason; Yuexi Chen; Mark D M Leiserson; Roded Sharan
Journal:  Genome Med       Date:  2021-11-01       Impact factor: 11.117

10.  Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.

Authors:  Nicola Giesen; Nagarajan Paramasivam; Umut H Toprak; Daniel Huebschmann; Jing Xu; Sebastian Uhrig; Mehmet Samur; Stella Bähr; Martina Fröhlich; Sadaf S Mughal; Elias K Mai; Anna Jauch; Carsten Müller-Tidow; Benedikt Brors; Nikhil Munshi; Hartmut Goldschmidt; Niels Weinhold; Matthias Schlesner; Marc S Raab
Journal:  Haematologica       Date:  2022-08-01       Impact factor: 11.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.